The biomarker for biological age that reflects lifestyle immediately

Most longevity biomarkers share a fundamental problem: they either barely respond to lifestyle changes, or the signal takes years to appear. Anyone who wants to show their clients that an intervention is actually working needs something different. N-glycans of immunoglobulin G antibodies are among the few aging biomarkers that do both — they correlate strongly with biological age and respond to behavior within months. That makes them particularly relevant in practice.

What N-glycans are

Antibodies of the immunoglobulin G (IgG) class carry a sugar chain at a defined position in their structure — a so-called N-glycan. This sugar chain is not a structural footnote. It functionally determines whether an antibody acts in a more pro-inflammatory or anti-inflammatory way.

And its composition changes systematically with age.

That is the core point: the signal is not the presence of IgG itself, but the fine structure of its sugar chain. Knowing the glycan profile means knowing something about a person's inflammatory status — and about their biological age.

What the study did

Krištić et al. (2014) published in The Journals of Gerontology what remains the most comprehensive analysis of IgG glycosylation and aging to date. The sample: 5,117 individuals from four European cohorts, measured by high-resolution UPLC analysis. The study is available open access.

The pattern is consistent across all four cohorts:

  • Galactosylation and sialylation of IgG N-glycans decrease with age.
  • The proportion of agalactosylated structures increases.
  • The result: the antibody sugar coat shifts systematically toward a pro-inflammatory profile.

Certain glycan combinations explained up to 58 percent of the variance in chronological age in this analysis — a magnitude at which classic biomarkers such as telomere length perform considerably worse. The full article is available at Oxford Academic.

Why this is different from other biomarkers

Two points make IgG glycans particularly interesting in practice — and distinguish them from most other aging biomarkers.

First: mechanistic relevance.
The age-related shift in glycan profile is not merely a statistical correlation. It is mechanistically linked to chronic, low-grade inflammation — the so-called inflammaging. This is precisely the systemic inflammatory state that precedes many age-associated diseases and that often remains invisible in the space between "not ill" and "optimally healthy."

Second: intervention sensitivity.
Unlike DNA methylation age or telomere length, glycan profiles respond to lifestyle changes in a measurable and comparatively timely way. Greto et al. (2021, International Journal of Obesity) showed that substantial weight loss significantly reduces glycan age. Studies on exercise interventions and hormone therapy point in the same direction.

This means that practitioners working with clients on nutrition, movement, or sleep can use glycan changes as a progress marker — within a timeframe that is workable in practice.

Why this matters in practice

A marker that responds to behavior within months is fundamentally different to work with than one that takes years to produce a signal.

It allows genuine before-and-after comparisons of an intervention. This has two direct effects.

On the client side, it creates visible motivation. Someone who sees that their biological age has measurably changed will stay the course. Compliance is not an act of willpower — it is a function of feedback.

On the Health Professional side, it creates a basis for steering. Not a gut feeling about whether an intervention is working, but a documented data point. That is the difference between guided support and care based on assumption.

Where we are heading at SLOW

Glycans alone are not a complete picture. That is the point.

Precise means, in our understanding, that biological age is not captured by a single marker. IgG glycans, hsCRP, high-resolution inflammatory markers, HRV progression, cardiorespiratory fitness, and metabolic values together produce a considerably more robust picture than any individual value on its own. For commercial glycan measurement, options such as the GlycanAge test exist — one possibility among several within an individually assembled diagnostic set.

Holistic means that glycan shifts arise from a systemic context. Nutrition, movement, sleep, stress, hormonal status, smoking, alcohol, and chronic infections all influence glycosylation. Anyone who wants to move the marker is changing systems — not applying a single measure.

Within the SLOW platform, Health Professionals translate exactly these data layers into a protocol tailored to the individual client. Not generic, but context-specific. From data to outcomes — measurable, documented, sustainable.

Are you already using glycan measurements in your practice? And how do you combine them with classic inflammatory and metabolic markers for progress assessment? Write it in the comments — this is a discussion we are glad to continue.

Source: Krištić J, Vučković F, Menni C, Klarić L, et al. Glycans Are a Novel Biomarker of Chronological and Biological Ages. The Journals of Gerontology Series A, 69(7), 779–789 (2014). DOI: 10.1093/gerona/glt190